Last reviewed · How we verify
NCT07524816
Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
trial testing CAR-T cell therapy in Large B-Cell Lymphoma (LBCL) in 76 participants. Currently enrolling.
1 January 2028
Quick facts
| Lead sponsor | N.N. Alexandrov National Cancer Centre |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 76 |
| Start date | 1 June 2021 |
| Primary completion | 1 January 2028 |
| Estimated completion | 1 January 2029 |
| Sites | 1 location across Belarus |
Drugs / interventions tested
- CAR-T cell therapy
Conditions studied
- Large B-Cell Lymphoma (LBCL) — all drugs for Large B-Cell Lymphoma (LBCL) →
Sponsor
N.N. Alexandrov National Cancer Centre
Who can join
Adults 18 to 80, any sex, with Large B-Cell Lymphoma (LBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed/refractory large B-cell lymphomas (R/R LBCLs) since 2018. However, high cost of commercial products limits their application in real-world clinical practice. Academic approach to manufacturing CAR-T cell products can reduce the costs and improve availability and affordability of this therapy option. The aim of the present study is assess the efficacy and safety of the use of academic CAR-T cell products in r/r LBCL patients.This prospective observational study with r/r LBCL patients treated in the NN Alexandrov National Cancer Centre of Belarus. The CAR-T cell product was manufactured using lentiviral vector encoding anti-CD19 CAR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07524816
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR-T cell therapy
Trials testing the same drug.
- NCT07344818 — An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressi · EARLY_PHASE1 · recruiting
- NCT06649227 — Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19 · Phase 1 · recruiting
- NCT06439173 — Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Ther · recruiting
- NCT06238336 — Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours · Phase 2, PHASE3 · unknown
Other recruiting trials for Large B-Cell Lymphoma (LBCL)
Currently open trials in the same condition.
- NCT06526793 — Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL · Phase 2 · recruiting
- NCT07461831 — CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma · Phase 2 · recruiting
- NCT04661020 — CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma · Phase 2 · recruiting
Other N.N. Alexandrov National Cancer Centre trials
Trials by the same sponsor.
- NCT07308990 — Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients With Localized or Locally Advance · NA · recruiting
- NCT07472153 — PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemother · Phase 2, PHASE3 · recruiting
- NCT07472140 — PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficie · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07524816 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by N.N. Alexandrov National Cancer Centre
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07524816.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing